Evolocumab, a cholesterol-lowering drug, has been shown to be effective in preventing heart attacks. The study showed that it reduced the risk of a first heart attack and stroke by 31% in high-risk diabetes patients who do not yet have established cardiovascular disease. The drug is commonly used in patients with existing cardiovascular disease. The results indicate the potential of evolocumab in the primary prevention of cardiovascular events in risk groups.